respiratori
tract
infect
common
caus
ill
among
patient
cancer
substanti
sourc
morbid
mortal
data
regard
incid
epidemiolog
respiratori
tract
infect
cancer
patient
limit
cancer
identifi
second
lead
caus
death
unit
state
nearli
death
influenza
pneumonia
list
number
compris
death
mortal
nation
vital
statist
report
list
due
singl
caus
substanti
amount
mortal
due
combin
cancer
pneumonia
addit
fourth
lead
caus
death
chronic
lower
respiratori
diseas
eg
chronic
obstruct
pulmonari
diseas
overlap
lung
cancer
pneumonia
document
infect
patient
febril
neutropenia
eventu
document
pneumonia
thu
although
detail
understand
morbid
mortal
associ
pneumonia
patient
malign
limit
burden
substanti
respiratori
tract
infect
often
divid
upper
lower
respiratori
tract
infect
upper
respiratori
tract
infect
primarili
involv
nose
pharynx
adjac
structur
lower
respiratori
tract
infect
often
defin
evid
infect
respiratori
symptom
physic
examin
find
suggest
lower
respiratori
tract
diseas
abnorm
chest
imag
lower
respiratori
tract
infect
includ
bronchiti
bronchiol
eg
young
children
pneumonia
detail
discuss
upper
respiratori
tract
infect
beyond
scope
book
chapter
includ
within
upper
respiratori
tract
infect
pharyng
rhiniti
otiti
media
sinus
major
upper
respiratori
infect
due
viral
etiolog
although
pharyng
may
due
viral
etiolog
eg
herp
simplex
viru
cytomegaloviru
epstein
barr
viru
chemotherapi
radiationinduc
mucos
bacteri
etiolog
eg
streptococcu
pyogen
commonli
may
also
occur
rare
perior
infect
involv
floor
mandibl
rapidli
dissect
tissu
plane
neck
caus
ludwig
angina
diseas
process
bull
neck
develop
potenti
airway
narrow
respiratori
compromis
risk
progress
mediastinum
lemierr
syndrom
also
develop
due
spread
infect
perior
space
soft
tissu
neck
caus
septic
thrombophleb
jugular
vein
septic
emboli
lung
fusobacterium
oral
anaerob
commonli
respons
infect
uncommon
potenti
life
threaten
otiti
media
sinus
occur
patient
underli
malign
healthi
patient
infect
commonli
due
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
patient
chronic
diseas
staphylococcu
aureu
enter
gramneg
bacteria
anaerob
also
occur
set
neutropenia
chronic
graft
versu
host
diseas
gvhd
possibl
invas
fungal
sinus
entertain
aggress
evalu
patient
develop
symptom
potenti
consist
sinus
rapid
develop
ocular
find
cranial
nerv
palsi
mental
statu
chang
set
sinus
prompt
emerg
sinu
imag
evalu
otolaryngologist
possibl
surgic
debrid
biopsi
failur
respond
usual
empir
antibiot
therapi
also
prompt
addit
imag
possibl
invas
strategi
identifi
pathogen
evalu
complic
lower
respiratori
tract
infect
classic
includ
bronchiti
bronchiol
pneumon
pneumonia
term
poorli
defin
substanti
overlap
exist
differenti
entiti
individu
patient
may
difficult
chapter
refer
lower
tract
respiratori
diseas
pneumonia
unless
otherwis
specifi
epidemiolog
studi
clinic
trial
pneumonia
requir
patient
evid
acut
ill
eg
fever
leukocytosi
sever
leukopenia
evid
acut
respiratori
symptom
eg
cough
dyspnea
tachypnea
abnorm
breath
sound
abnorm
imag
chest
suggest
pulmonari
abnorm
eg
lobar
consolid
unfortun
mani
clinic
trial
pneumonia
exclud
patient
underli
malign
guidelin
adequ
address
issu
patient
popul
differenti
diagnosi
pulmonari
infiltr
broad
outlin
tabl
consider
includ
cardiac
pulmonari
malign
inflammatori
infecti
process
notabl
cardiac
pulmonari
toxic
comorbid
medic
condit
eg
rheumatoid
arthriti
medic
eg
amiodaron
occur
set
cancer
manag
cardiotox
chemotherapeut
agent
cyclophosphamid
anthracyclin
mitoxantron
paclitaxel
docetaxel
trastuzumab
mediastin
radiat
alway
consid
potenti
caus
cardiovascular
dysfunct
may
present
primarili
respiratori
symptom
similarli
interstiti
pneumon
may
result
treatment
bleomycin
cyclophosphamid
gemcitabin
cytarabin
fluorouracil
procarbazin
gefitinib
rituximab
mani
agent
addit
inhibitor
mammalian
target
rapamycin
mtor
sirolimu
everolimu
temsirolimu
caus
progress
noninfecti
pneumon
complic
cancer
treatment
volum
overload
acut
lung
injuri
blood
transfus
pulmonari
embol
diffus
alveolar
hemorrhag
also
consid
primari
lung
cancer
metastat
diseas
also
result
pulmonari
opac
sometim
malign
particularli
primari
lung
cancer
obstruct
imped
air
flow
lung
result
postobstruct
pneumonia
lung
abscess
radiat
pneumon
particularli
associ
fever
elev
white
blood
cell
count
often
difficult
distinguish
infecti
pneumon
infiltr
radiat
pneumon
perivascular
hazi
progress
patchi
alveolar
fill
infiltr
addit
multipl
diseas
process
simultan
occur
lung
possibl
entertain
indwel
cathet
infect
must
also
consid
patient
symptom
infect
pulmonari
infiltr
chest
imag
indwel
cathet
dramat
increas
risk
bloodstream
infect
endocard
bacteremia
rightsid
endocard
result
embol
pulmonari
infiltr
typic
peripher
respiratori
distress
bacteremia
sepsi
also
result
capillari
leak
associ
diffus
patchi
infiltr
acut
respiratori
distress
syndrom
ard
certain
epidemiolog
risk
factor
exist
pneumonia
ascertain
factor
individu
patient
help
expand
alter
differenti
diagnosi
histori
cigarett
smoke
identifi
strongest
epidemiolog
risk
factor
invas
pneumococc
diseas
immunocompet
nonelderli
adult
season
year
consid
mani
respiratori
viral
infect
occur
predominantli
winter
spring
eg
influenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
children
particularli
daycar
may
transmit
respiratori
virus
rsv
influenza
risk
factor
invas
pneumococc
diseas
sick
contact
also
may
sourc
less
commonli
observ
infect
tuberculosi
measl
histori
exposur
tuberculosi
import
sinc
may
remain
latent
state
year
reactiv
increas
age
immun
deplet
import
consid
approxim
tuberculosi
case
diagnos
unit
state
occur
individu
born
outsid
unit
state
geograph
factor
also
help
consid
endem
fungi
histoplasmosi
mississippi
ohio
river
valley
coccidioidomycosi
desert
southwest
particularli
san
joaquin
valley
frequent
observ
cancer
patient
although
blastomycosi
frequent
mistaken
lung
cancer
metastat
malign
symptomat
diseas
uncommon
cancer
may
occur
frequent
defect
cellmedi
immun
exposur
certain
pet
parakeet
parrot
caus
psittacosi
anim
birth
livestock
result
risk
infect
coxiella
burnetti
qfever
suggest
uncommon
caus
pneumonia
ongo
construct
medic
center
without
appropri
protect
measur
exposur
aerosol
soil
result
increas
risk
aspergillu
pneumonia
nosocomi
risk
factor
aspergillu
also
legionella
infect
outlin
elsewher
volum
chapter
recent
histori
preced
current
viral
ill
obtain
known
coinfect
mix
infect
identifi
communityacquir
pneumonia
cap
improv
diagnost
test
particularli
recent
applic
pcr
test
respiratori
viral
pathogen
result
greater
appreci
interact
occur
bacteri
viral
pathogen
previous
healthi
children
adult
admit
pneumonia
virus
bacteria
identifi
use
molecular
techniqu
addit
virus
eg
influenza
rsv
human
metapneumoviru
import
role
predispos
patient
invas
bacteri
pneumonia
casecontrol
studi
prior
influenza
infect
week
predispos
children
subsequ
sever
pneumococc
pneumonia
requir
hospit
odd
ratio
influenza
infect
also
risk
factor
sever
aureu
pneumonia
particularli
methicillinresist
aureu
mrsa
recent
review
autopsi
patient
die
influenza
pandem
suggest
much
mortal
actual
due
bacteri
superinfect
other
also
identifi
pneumonia
frequent
nasopharyng
secret
sever
novel
diseas
mild
case
addit
pediatr
data
suggest
invas
pneumococc
diseas
correl
preced
rsv
infect
week
later
preced
human
metapneumoviru
influenza
infect
week
later
note
pneumococc
vaccin
children
associ
decreas
lower
respiratori
tract
infect
caus
influenza
parainfluenza
rsv
human
metapneumoviru
thu
although
data
lack
specif
cancer
patient
popul
recent
data
suggest
virus
may
predispos
subsequ
bacteri
infect
bacteria
virus
commonli
coidentifi
pneumonia
addit
baselin
epidemiolog
risk
factor
relat
underli
malign
assess
exampl
lung
cancer
patient
underli
chronic
obstruct
pulmonari
diseas
copd
multipl
prior
copd
exacerb
risk
differ
pulmonari
pathogen
hematolog
malign
patient
addit
specif
tumor
stage
malign
also
help
suggest
potenti
oncologyrel
risk
factor
exampl
patient
known
brain
metastas
higher
risk
aspir
pneumonia
patient
without
metastat
diseas
risk
factor
aspir
includ
impair
swallow
especi
head
neck
cancer
alter
mental
statu
procedur
requir
sedat
sever
point
bear
particular
emphasi
first
immun
deficit
occur
underli
hematolog
malign
eg
multipl
myeloma
result
deficit
humor
immun
increas
risk
encapsul
organ
pneumonia
h
influenza
second
strategi
use
diagnos
treat
underli
malign
also
increas
risk
pneumonia
due
certain
pathogen
exampl
although
uncommonli
perform
splenectomi
strongli
associ
increas
risk
infect
encapsul
organ
prolong
administr
steroid
increas
risk
invas
fungal
pathogen
pneumocysti
jiroveci
pneumonia
pcp
administr
antilymphocyt
antibodi
result
sever
deplet
cell
place
patient
risk
cellmedi
infect
reactiv
latent
infect
increasingli
recogn
delay
lymphocyt
reconstitut
perhap
marker
delay
reconstitut
certain
lymphocyt
popul
significantli
impact
recoveri
certain
viral
infect
adenoviru
depth
durat
neutropenia
occur
chemotherapi
directli
increas
risk
bacteri
fungal
notabl
final
impair
mucos
defens
due
cytotox
chemotherapi
also
increas
risk
invas
bacteri
pathogen
impair
mucou
clearanc
respiratori
tract
increas
risk
invas
respiratori
tract
infect
engraft
particularli
cell
engraft
better
peripher
blood
stem
cell
transplant
sct
bone
marrow
transplant
bmt
fewer
fungal
bacteri
viral
infect
occur
transplant
despit
improv
pneumonia
frequent
complic
sct
two
import
factor
impact
risk
infect
transplant
presenc
absenc
gvhd
time
transplant
classic
preengraft
period
usual
less
week
bacteri
infect
candida
aspergillu
hsv
among
common
pathogen
engraft
day
sct
impact
defici
cellmedi
immun
result
increas
risk
cmv
pcp
aspergillu
infect
late
phase
day
reactiv
cmv
vzv
infect
encapsul
bacteria
eg
pneumococcu
common
risk
correl
sever
prior
gvhd
addit
develop
invas
aspergillu
infect
month
transplant
associ
chronic
gvhd
prior
cmv
diseas
notabl
risk
seriou
ill
respiratori
virus
remain
elev
throughout
transplant
also
import
factor
impact
risk
infect
transplant
allogen
sct
recipi
higher
risk
infecti
complic
autolog
sct
recipi
uncommon
autolog
sct
recipi
infecti
complic
month
allogen
sct
recipi
continu
measur
humor
cellmedi
reticuloendotheli
system
deficit
receipt
hlamismatch
unrel
donor
transplant
also
independ
risk
factor
latent
viral
reactiv
invas
fungal
diseas
impact
tcell
deplet
monoclon
antibodi
alemtuzumab
upon
subsequ
risk
reactiv
latent
infect
cmv
develop
new
infect
underestim
prior
cmv
major
risk
factor
subsequ
invas
fungal
diseas
import
risk
factor
invas
aspergillosi
engraft
includ
gvhd
receipt
corticosteroid
neutropenia
lymphopenia
respiratori
viru
infect
hospit
patient
remain
risk
nosocomi
acquisit
respiratori
virus
influenza
parainfluenza
rsv
adenoviru
known
caus
larg
outbreak
transplant
center
season
virus
appear
close
approxim
healthi
popul
common
uncommon
organ
respons
pneumonia
cancer
patient
outlin
tabl
cancer
patient
heterogen
group
individu
may
pathogen
may
close
resembl
organ
observ
patient
cap
hospitalacquir
pneumonia
hap
pneumonia
immunosuppress
patient
exampl
prostat
cancer
patient
hormon
therapi
outpati
colon
cancer
prior
bone
marrow
suppress
like
pathogen
mirror
cap
contrast
surgic
complic
colon
cancer
patient
requir
prolong
stay
surgic
intens
care
unit
mechan
ventil
predispos
pathogen
commonli
observ
hap
sct
recipi
develop
pneumonia
neutropen
infect
pathogen
observ
immunosuppress
patient
could
pathogen
like
patient
hap
pneumonia
develop
hospit
even
cap
patient
year
sct
immun
reconstitut
underli
gvhd
well
organ
caus
aspir
pneumonia
consid
patient
cancer
either
comorbid
condit
medic
use
place
heighten
risk
aspir
eg
alter
mental
statu
mucos
narcot
benzodiazepin
use
one
recent
studi
document
cancer
patient
underw
bronchoalveolar
lavag
bal
multipl
pathogen
identifi
thu
physician
care
cancer
patient
pneumonia
care
consid
potenti
pathogen
particular
import
consider
prior
microbiolog
isol
identifi
patient
prior
antiinfect
therapi
adher
tmpsmx
prophylaxi
greatli
decreas
risk
pcp
prophylact
regimen
pcp
gener
effect
also
lack
protect
tmpsmx
provid
bacteria
nocardia
prior
antibiot
administr
broadspectrum
agent
place
patient
risk
infect
drugresist
pathogen
exampl
prior
levofloxacin
administr
previous
associ
acquisit
fluoroquinoloneresist
pneumonia
infect
prior
administr
antivir
acyclovir
ganciclovir
oseltamivir
may
substanti
decreas
risk
infect
infect
occur
may
due
drugresist
viral
pathogen
multipl
author
document
prior
administr
voriconazol
sct
recipi
risk
factor
breakthrough
fungal
infect
due
mucormycosi
rhizopu
herp
simplex
viru
hsv
infect
occasion
involv
lung
sinc
hsv
reactiv
bmt
recipi
recommend
acyclovir
prophylaxi
administ
sct
recipi
engraft
occur
mucos
resolv
import
consid
hsv
potenti
pathogen
lung
particularli
patient
perior
lesion
mucos
although
hsv
identifi
bronchial
fluid
pcr
routin
test
molecular
laboratori
viral
cultur
rapid
shell
vial
dfa
test
easili
identifi
hsv
treatment
highdos
acyclovir
resist
acyclovir
occur
mutat
thymidin
kinas
gene
rare
mutat
hsv
dna
polymeras
altern
includ
nephrotox
medic
foscarnet
cidofovir
although
occasion
resist
develop
see
chapter
cmv
particularli
cmv
pneumon
previous
common
caus
death
bmt
recipi
declin
aggress
monitor
treatment
cmv
reactiv
consist
identifi
risk
factor
cmv
diseas
includ
cmv
seroposit
gvhd
lymphopenia
use
alemtuzumab
cmv
establish
latenc
thu
isol
cmv
viral
cultur
peripher
site
eg
nasopharyng
urin
stool
poorli
predict
identifi
patient
develop
subsequ
invas
cmv
diseas
patient
develop
diseas
peripher
cultur
enough
time
grow
although
cmv
antigen
test
blood
result
rapid
identif
limit
need
larg
blood
volum
could
use
neutropen
patient
advent
pcr
test
blood
improv
detect
cmv
neutropen
patient
associ
improv
surviv
viral
cultur
treatment
patient
cmv
physician
remain
awar
risk
subsequ
bacteri
fungal
infect
substanti
increas
epidem
novel
dramat
impact
hospit
admiss
spring
fall
capac
replic
within
human
lung
tissu
caus
diffus
viral
pneumon
associ
sever
hypoxemia
ard
sometim
multisystem
organ
failur
case
sever
ill
occur
patient
year
age
underli
immunosuppress
present
patient
diseas
requir
hospit
retrospect
singl
cancercent
studi
conduct
note
occur
commonli
among
patient
underli
hematolog
malign
among
solid
tumor
patient
present
cough
fever
thirtyseven
percentag
patient
requir
hospit
assess
radiograph
lower
respiratori
tract
diseas
almost
patient
receiv
neuraminidas
therapi
receiv
clinic
present
none
patient
requir
mechan
ventil
die
due
diseas
earli
administr
oseltamivir
patient
influenza
associ
better
outcom
lower
risk
death
thu
influenza
occur
commun
empir
therapi
influenza
institut
patient
compat
symptom
await
result
test
addit
therapi
continu
patient
neg
test
sever
progress
diseas
exist
altern
diagnosi
establish
due
pcr
fals
neg
specimen
notabl
healthi
patient
continu
shed
season
influenza
pcr
day
onset
ill
viral
shed
may
even
prolong
hospit
patient
patient
underli
immunosuppress
uncertain
whether
detect
influenza
genet
materi
repres
viabl
replic
viru
delay
viral
clearanc
associ
late
initi
oseltamivir
associ
comorbid
prolong
hospit
stay
chest
radiographi
chest
xray
necessari
routin
evalu
patient
suspect
pneumonia
due
superior
sensit
specif
physic
examin
recommend
cancer
patient
febril
neutropen
respiratori
sign
symptom
use
suggest
potenti
etiolog
eg
congest
heart
failur
pathogen
interstiti
peribronchi
infiltr
classic
associ
viral
pathogen
lobar
alveolar
infiltr
frequent
seen
bacteri
pathogen
howev
substanti
overlap
exist
children
document
bacteri
pneumonia
airspac
diseas
children
influenza
pulmonari
infiltr
may
alveolar
compon
infiltr
influenza
radiograph
find
commonli
includ
diffus
mix
interstiti
alveolar
infiltr
patient
bacteri
superinfect
lobar
multilobar
distribut
occur
chest
radiographi
also
help
identifi
complic
defin
necrot
pneumonia
lung
abscess
locul
pleural
fluid
empyema
presenc
effus
suggest
bacteri
pneumonia
aureu
pyogen
later
decubitu
film
use
determin
whether
effus
associ
pneumonia
freeflow
locul
suggest
failur
fluid
move
depend
region
chest
chang
posit
chest
xray
particularli
limit
earli
detect
pneumonia
patient
cancer
particularli
obtain
supin
posit
also
well
known
delay
chest
xray
appear
pneumonia
occur
thu
patient
high
clinic
suspicion
pneumonia
treat
presumpt
h
repeat
chest
xray
highresolut
ct
scan
improv
sensit
specif
pneumonia
chest
xray
patient
without
underli
cancer
sensit
chest
xray
comparison
ct
scan
shown
one
studi
use
highresolut
ct
scan
result
median
increas
day
time
detect
pulmonari
infiltr
use
chest
xray
alon
importantli
neg
highresolut
ct
scan
individu
develop
inflammatori
lung
lesion
within
next
day
develop
inflammatori
lung
lesion
within
next
day
ct
angiographi
help
evalu
pulmonari
embol
also
common
oncolog
patient
still
prove
substanti
inform
lung
parenchyma
mediastin
lymphadenopathi
although
classic
find
ct
imag
includ
consolid
bacteri
diseas
nodul
fungal
diseas
perihilar
ground
glass
opac
pcp
mosaic
pattern
ground
glass
opac
viral
diseas
find
nonspecif
diagnost
ct
help
suggest
noninfecti
etiolog
eg
radiat
pneumon
drug
toxic
malign
provid
precis
local
infiltr
subsequ
diagnost
procedur
certain
characterist
strongli
associ
invas
aspergillu
set
neutropenia
find
includ
presenc
halo
sign
area
hemorrhag
around
nodular
lesion
presenc
aircresc
sign
find
strongli
suggest
aspergillu
also
occur
infect
pseudomona
aeruginosa
nocardia
zygomycet
fusarium
scedosporium
classic
find
sensit
find
observ
invas
pulmonari
aspergillosi
larg
multicent
studi
invas
aspergillu
least
one
macronodul
defin
cm
halo
sign
consolid
infarctshap
macronodul
cavit
aircresc
sign
interestingli
good
prognost
sign
find
halo
sign
correl
improv
respons
therapi
surviv
imag
test
may
appropri
depend
clinic
set
exclud
diagnos
exampl
brain
natriuret
peptid
bnp
echocardiographi
may
benefici
individu
patient
exclud
congest
heart
failur
transesophag
echocardiographi
sensit
transthorac
echocardiographi
endocard
use
adult
patient
endocard
strongli
consid
differenti
diagnosi
tabl
outlin
routin
supplement
test
may
potenti
benefit
patient
underli
malign
present
pneumonia
although
blood
cultur
identifi
pathogen
patient
cap
particularli
import
patient
underli
malign
etiolog
eg
central
line
infect
embol
lung
lesion
must
consid
sputum
cultur
although
univers
recommend
like
higher
benefit
patient
underli
malign
common
pathogen
less
frequent
observ
obtain
sputum
cultur
prior
antibiot
administr
increas
yield
particular
help
identifi
pathogen
empir
coverag
may
adequ
cover
eg
mrsa
drugresist
gramneg
rod
number
test
presenc
antigen
develop
identifi
fungal
bacteri
pathogen
sever
import
caveat
exist
antigen
test
first
antigen
test
sensit
much
less
thu
view
test
rule
presenc
pathogen
second
antigen
test
sensit
shortli
initi
treatment
agent
activ
specif
pathogen
test
gener
becom
neg
fairli
quickli
case
eg
histoplasmosi
use
gaug
respons
therapi
final
test
sensit
set
dissemin
diseas
pneumonia
alon
urinari
antigen
assay
legionella
sensit
specif
serogroup
pneumonia
sensit
approach
specif
obtain
patient
fail
outpati
antibiot
therapi
pleural
effus
requir
intens
care
admiss
pneumonia
recogn
mani
legionella
speci
caus
pneumonia
detect
urinari
antigen
diagnos
speci
cultur
pcr
respiratori
specimen
necessari
patient
risk
endem
fungal
diseas
urinari
antigen
test
exist
histoplasmosi
blastomycosi
coccidiodiomycosi
excel
sensit
risk
crossreact
fungal
pathogen
includ
endem
fungi
penicillium
respons
therapi
follow
obtain
serial
specimen
urinari
antigen
test
serum
antigen
test
also
exist
limit
evalu
certain
invas
fungal
pathogen
first
cryptococc
latex
antigen
test
wide
avail
consid
patient
cellmedi
immun
deficit
antigen
test
fungitel
bg
associ
cape
cod
east
falmouth
mass
develop
detect
cell
wall
compon
aspergillu
fungi
thu
specif
aspergillu
found
posit
patient
candidemia
cyptococcosi
fusariosi
pcp
histoplasmosi
sensit
test
aspergillu
rang
specif
rang
clinic
practic
assay
found
help
discrimin
fungal
bacteri
infect
intens
care
unit
set
even
healthi
popul
falseposit
rate
observ
may
even
higher
popul
risk
invas
fungal
infect
fals
posit
also
observ
certain
medic
follow
hemodialysi
use
iv
tube
filter
administr
albumin
immunoglobulin
exposur
gauz
addit
echinocandin
interfer
synthesi
administr
echinocandin
eg
caspofungin
micafungin
anidulafungin
may
associ
fals
neg
assay
anoth
antigen
test
platelia
biorad
laboratori
redmond
wa
aspergillu
enzym
immunoassay
sensit
specif
invas
aspergillosi
perform
blood
specimen
best
cutoff
aspergillu
galactomannan
test
optim
sensit
maintain
high
degre
specif
area
intens
investig
obtain
aspergillu
eia
twice
weekli
sampl
result
earlier
diagnosi
invas
pulmonari
aspergillosi
unfortun
falseneg
falseposit
result
occur
aspergillu
galactomannan
test
administr
associ
falseposit
test
may
due
galactomannan
carri
drug
product
process
stage
penicillium
falseposit
test
also
occur
receipt
penicilliumderiv
antibiot
includ
amoxicillin
ticarcillin
without
betalactamas
inhibitor
addit
falseposit
test
occur
patient
infect
endem
fungi
fusarium
rhodotorula
trichophyton
penicillium
paecilomyc
alternaria
speci
plasmalyt
baxter
healthcar
corpor
electrolyt
replac
solut
contain
sodium
glucon
produc
aspergillu
flavu
also
associ
falseposit
aspergillu
galactomannan
test
probabl
frequent
caus
falseneg
aspergillu
galactomannan
test
administr
moldact
antifung
therapi
marr
et
al
demonstr
sensit
galactomannan
test
fell
patient
receiv
moldact
antifung
therapi
falseneg
result
also
note
patient
local
aspergillu
infect
diagnosi
invas
fungal
infect
difficult
patient
cancer
sct
result
european
organ
research
treatment
cancer
mycos
studi
group
set
guidelin
definit
probabl
possibl
invas
fungal
infect
part
due
difficulti
exist
obtain
tissu
diagnosi
would
prove
invas
fungal
diseas
gener
host
factor
predispos
patient
fungal
infect
eg
neutropenia
gvhd
clinic
featur
fungal
infect
eg
ct
imag
show
halo
sign
aircresc
sign
sinus
mycolog
evid
infect
eg
posit
antigen
test
posit
cultur
must
present
demonstr
probabl
case
invas
fungal
diseas
clinic
practic
mani
case
possibl
case
dissuad
clinician
treat
invas
fungal
diseas
sinc
guidelin
primarili
written
help
develop
common
research
definit
retrospect
studi
md
anderson
clinic
characterist
risk
factor
abl
separ
pulmonari
zygomycosi
invas
pulmonari
aspergillosi
risk
factor
zygomycosi
infect
includ
voriconazol
prophylaxi
concomit
sinus
pulmonari
nodul
pleural
effus
initi
ct
scan
author
observ
differ
ct
scan
find
commonli
associ
pulmonari
mold
infect
mass
caviti
halo
sign
aircresc
sign
anoth
studi
group
sinu
involv
alon
combin
pulmonari
diseas
strongli
suggest
invas
zygomycosi
comparison
aspergillu
commonli
perform
viral
test
strategi
outlin
tabl
past
sever
year
increas
realiz
poor
sensit
rapid
antigen
test
identifi
viral
pathogen
increas
relianc
upon
use
pcr
past
mani
homebrew
pcrbase
assay
use
variou
center
mani
center
pcr
avail
test
common
respiratori
pathogen
eg
influenza
rsv
cmv
center
also
access
fdaapprov
xtag
respiratori
viral
panel
luminex
corp
austin
tx
abil
test
influenza
b
rsv
b
parainfluenza
type
adenoviru
human
metapneumoviru
rhinoviru
realtim
pcr
provid
rapid
result
quantit
also
detect
multipl
virus
simultan
recent
retrospect
studi
sct
recipi
quantit
pcr
viral
load
respiratori
viru
rna
bal
specimen
correl
subsequ
mechan
ventil
death
contrast
patient
studi
viral
rna
detect
serum
specimen
die
multivari
analysi
detect
viral
rna
serum
associ
adjust
rel
risk
death
within
day
comparison
virem
result
remain
confirm
could
provid
use
prognost
inform
futur
sever
caveat
pcr
test
viral
pathogen
emphas
pcr
identif
viru
may
indic
recent
infect
activ
diseas
data
lack
cancer
patient
healthi
infant
prolong
shed
rsv
realtim
pcr
observ
day
symptom
begin
although
pcr
consid
gold
standard
diagnosi
pcr
specimen
upper
lower
respiratori
tract
fals
neg
patient
addit
crosscontamin
sampl
easili
occur
pcr
result
falseposit
test
thu
pcr
result
alway
view
context
clinic
scenario
patient
addit
respiratori
specimen
type
obtain
patient
clinic
impress
discord
test
result
final
screen
tuberculosi
perform
either
ppd
skin
test
new
blood
test
call
interferongamma
releas
assay
igra
test
patient
blood
mix
vitro
tuberculosisspecif
antigen
result
releas
interferon
gamma
cell
previous
expos
tuberculosi
benefit
test
potenti
crossreact
patient
previous
expos
bcg
vaccin
administ
routin
countri
world
tuberculosi
endem
recogn
ppd
least
sensit
detect
prior
tuberculosi
diseas
patient
activ
infect
tuberculosi
exampl
studi
africa
tb
hivinfect
patient
igra
sensit
ppd
sensit
ppd
igra
least
sensit
count
data
regard
use
igra
lack
patient
activ
tuberculosi
cancer
thu
neither
neg
ppd
neg
igra
rule
possibl
activ
tuberculosi
instead
anyon
suspect
activ
pulmonari
tuberculosi
immedi
place
neg
pressur
isol
undergo
sputum
evalu
tuberculosi
obtain
etiolog
diagnosi
also
help
avoid
prolong
broadspectrum
antibiot
administr
avoid
antibiot
toxic
decreas
risk
bacteri
superinfect
eg
clostridium
difficil
thu
unusu
clinic
present
particularli
sever
pneumonia
eg
necessit
icu
admiss
intub
mechan
ventil
failur
respond
initi
empir
antimicrobi
therapi
within
h
prompt
aggress
diagnost
measur
attempt
obtain
deep
specimen
tissu
earli
clinic
cours
pneumonia
sever
issu
frequent
rais
object
diagnost
procedur
popul
first
patient
frequent
coagulopathi
due
underli
malign
chemotherapi
second
concern
may
exist
risk
introduc
infect
immunosuppress
third
mani
patient
clinic
unstabl
risk
need
substanti
respiratori
support
either
noninvas
mechan
ventil
routin
mechan
ventil
procedur
fourth
diagnost
procedur
consid
often
pretreat
broadspectrum
empir
coverag
thu
yield
procedur
often
low
final
procedur
best
yield
invas
like
result
complic
despit
frequent
potenti
issu
obtain
deep
specimen
tissu
often
quit
help
cultur
return
neg
sometim
provid
support
stop
empir
antibiot
escal
patient
well
may
also
provid
support
narrow
antibiot
administr
eg
stop
empir
mrsa
coverag
pcp
coverag
also
identifi
noninfecti
caus
fever
pulmonari
infiltr
malign
pulmonari
hemorrhag
unfortun
standard
approach
exist
manag
cancer
patient
need
diagnost
procedur
great
deal
centertocent
variabl
exist
way
patient
manag
center
littl
experi
certain
techniqu
limit
diagnost
option
locat
patient
infiltr
must
also
consid
peripher
pleuralbas
nodul
amen
bal
like
easili
reach
either
imagingguid
needl
biopsi
videoassist
thorascop
vat
biopsi
contrast
perihilar
medial
lesion
amen
bal
less
easili
access
imagingguid
needl
biopsi
vat
bronchoscopi
bal
probabl
least
invas
combin
protect
sampl
increas
yield
yield
approach
use
bal
combin
bal
transbronchi
biopsi
improv
yield
due
tissu
avail
patholog
review
requir
special
train
bronchoscopist
associ
higher
risk
bleed
pneumothorax
bal
fluid
test
aspergillu
galactomannan
sensit
specif
cutoff
use
note
like
antigen
test
sensit
may
impact
effect
treatment
patient
receiv
antimold
therapi
one
studi
open
thoracotomi
patient
malign
specif
diagnosi
reach
underw
biopsi
chang
manag
made
patient
procedur
infect
inflammatori
diseas
primarili
cryptogen
organ
pneumonia
malign
similar
contribut
specif
diagnosi
reach
yield
better
focal
infiltr
ventil
neutropen
complic
seen
individu
addit
benefit
approach
opportun
directli
visual
lesion
send
larger
piec
patholog
drain
coexist
effus
diagnost
therapeut
purpos
recent
studi
patient
histori
hematolog
malign
found
lung
lesion
subsequ
underw
ctguid
needl
biopsi
diagnost
yield
sinc
studi
includ
number
patient
without
evid
infect
yield
ctguid
needl
biopsi
may
lower
set
infecti
pulmonari
infiltr
patient
sever
pneumonia
requir
intub
aspir
endotrach
tube
shortli
intub
provid
import
inform
requir
patient
cooper
bypass
upper
airwaycolon
agent
regular
bronchoscopi
consid
techniqu
avail
institut
nonbronchoscop
bal
appear
higher
yield
less
contamin
endotrach
aspir
specimen
sent
studi
routin
sent
bronchoscopi
includ
viral
test
legionella
test
pcp
dfa
fungal
test
cytolog
see
tabl
pleural
effus
associ
earli
nonrespons
antimicrobi
therapi
ultim
clinic
failur
thu
current
cap
guidelin
recommend
perform
thoracentesi
individu
pleural
effus
cm
size
imag
cancer
patient
thoracentesi
provid
diagnost
benefit
potenti
identifi
pathogen
altern
diagnos
eg
metastasi
therapeut
benefit
improv
wall
interact
risk
includ
bleed
pneumothorax
care
examin
skin
perform
identifi
new
chang
skin
lesion
skin
provid
import
inform
system
infect
infect
due
cryptococcu
nocardia
aspergillu
pseudomona
fusarium
mycobacteria
spread
skin
pulmonari
sourc
skin
biopsi
minim
invas
sometim
provid
diagnost
inform
would
difficult
obtain
lung
site
sometim
also
help
eye
sinus
endopthalm
retin
lesion
suggest
fungal
diseas
addit
usual
bacteri
pathogen
aspergillu
mucormycosi
caus
sinu
diseas
note
howev
sinus
much
strongli
associ
zygomycosi
infect
aspergillu
approach
manag
lower
respiratori
tract
infect
includ
decis
whether
hospit
necessari
individu
patient
sever
sever
score
develop
decid
individu
cap
admit
common
sever
score
port
scorepneumonia
sever
index
psi
scale
take
account
underli
comorbid
instead
give
singl
point
factor
note
clinic
assess
confus
elev
urea
nitrogen
respiratori
rate
breathsmin
low
blood
pressur
age
year
point
factor
ad
togeth
valid
mortal
data
patient
score
mortal
thu
patient
score
often
treat
outpati
recommend
admit
gener
medic
ward
admit
intens
care
unit
import
realiz
take
account
patient
underli
malign
mortal
would
expect
even
higher
port
score
psi
complic
requir
addit
addit
variabl
take
account
underli
renal
diseas
liver
diseas
malign
higher
score
correl
higher
mortal
form
calcul
psi
wide
avail
internet
also
applic
pda
recommend
score
system
contribut
supersed
clinic
judgment
sever
score
system
underestim
mortal
patient
underli
malign
sever
score
system
valid
neither
hapvap
patient
neutropenia
sever
immunocompromis
appropri
empir
antimicrobi
coverag
crucial
optim
outcom
patient
cancer
pneumonia
prior
recent
antibiot
administr
taken
account
choos
empir
antibiot
regimen
pneumonia
patient
receiv
fluoroquinolon
prophylaxi
treat
empir
fluoroquinolon
becom
ill
addit
prior
colon
multidrugresist
pathogen
taken
account
empir
coverag
exampl
prior
colon
mrsa
prompt
empir
coverag
agent
known
activ
pathogen
eg
vancomycin
linezolid
note
daptomycin
effect
treatment
pneumonia
may
due
bind
drug
surfact
lung
addit
recent
drugresist
microbiolog
isol
eg
carbapenemresist
acinetobact
baumannii
carbapenemresist
klebsiella
pneumonia
identifi
patient
prompt
physician
modifi
empir
antibiot
includ
drug
includ
drugresist
pathogen
patient
minim
antimicrobi
exposur
health
care
contact
empir
coverag
regimen
cover
cap
patient
admit
may
appropri
eg
respiratori
fluoroquinolon
intraven
plu
macrolid
outpati
therapi
option
would
choic
respiratori
fluoroquinolon
oral
plu
macrolid
meet
criteria
hcap
hap
vap
risk
factor
drug
resist
usual
exist
empir
coverag
antipseudomon
carbapenem
plu
either
antipseudomon
fluoroquinolon
aminoglycosid
plu
agent
activ
mrsa
vancomycin
linezolid
warrant
set
neutropen
fever
empir
coverag
usual
appear
fairli
similar
hapvap
guidelin
although
coverag
agent
activ
atyp
organ
import
admit
home
eg
levofloxacin
macrolid
empir
coverag
aspir
may
also
necessari
influenza
depend
time
year
set
mdr
pathogen
carbapenemresist
baumannii
carbapenemresist
k
pneumonia
consult
local
infecti
diseas
specialist
encourag
help
make
recommend
base
local
antibiot
sensit
pattern
previous
discuss
failur
respond
empir
therapi
lead
reconsider
diagnosi
aggress
invas
diagnost
test
possibl
import
narrow
antibiot
coverag
avoid
place
patient
risk
colon
new
mdr
pathogen
infect
c
difficil
reduct
immunosuppress
achiev
consid
appropri
administr
chemotherapi
may
need
delay
acut
infect
resolv
treatment
cmv
pneumon
induct
dose
iv
ganciclovir
recommend
use
combin
hightit
cmvivig
ganciclovir
sinc
improv
note
comparison
histor
control
outcom
cancer
patient
influenza
usual
immunosuppress
durat
administr
day
instead
patient
pneumonia
progress
diseas
higher
dose
mg
given
twice
daili
consid
addit
patient
monitor
viral
clearanc
develop
oseltamivir
resist
consid
time
viral
clearanc
delay
intraven
formul
zanamivir
peramivir
exist
patient
sever
diseas
develop
oseltamivir
resist
associ
immunosuppress
fail
postexposur
oseltamivir
prophylaxi
prolong
administr
oseltamivir
current
almost
diseas
accumul
oseltamivir
resist
remain
suscept
zanamivir
activ
peramivir
oseltamivirresist
isol
notabl
season
almost
season
diseas
resist
adamantan
amantadin
rimantadin
certain
resist
season
influenza
continu
chang
current
recommend
review
prior
influenza
season
see
wwwcdcgovflu
classic
empir
administr
antimold
therapi
recommend
patient
persist
neutropen
fever
driven
number
older
studi
suggest
increas
mortal
patient
antifung
therapi
withheld
data
demonstr
benefit
earli
use
ct
scan
chest
aspergillu
galactomannan
test
result
recent
author
challeng
dogma
routin
administr
moldact
antifung
patient
prolong
neutropen
fever
limit
data
suggest
neg
highresolut
ct
scan
strategi
withhold
empir
antifung
therapi
associ
increas
risk
invas
fungal
infect
death
approach
consid
current
standard
practic
defin
guidelin
manag
febril
neutropenia
interest
approach
activ
area
research
empir
coverag
moldact
agent
liposom
amphotericin
echinocandin
recommend
among
neutropenia
actual
invas
fungal
diseas
subset
get
clinic
wors
usual
neutropenia
resolv
acut
inflammatori
respons
occur
site
preexist
fungal
infect
usual
therapi
fungal
infect
otherwis
outlin
chapter
increas
recognit
prior
treatment
regimen
cap
durat
may
necessari
may
associ
increas
risk
complic
c
difficil
data
cours
short
day
azithromycin
day
fluoroquinolon
exist
ventilatorassoci
pneumonia
random
control
trial
data
suggest
pathogen
day
suffici
although
patient
neutropenia
immunosuppress
longterm
steroid
exclud
trial
notabl
patient
nonfer
gramneg
rod
p
aeruginosa
baumanni
higher
risk
relaps
approach
other
suggest
use
addit
noninvas
test
procalcitonin
elev
bacteri
infect
viral
diseas
may
allow
physician
greatli
shorten
durat
therapi
pneumonia
data
shorten
antimicrobi
cours
lack
oncolog
patient
guidelin
recommend
day
appropri
infect
longer
absolut
neutrophil
count
cell
rise
evid
suggest
mortal
rate
elderli
patient
without
cancer
admit
cap
one
would
expect
mortal
rate
would
higher
patient
underli
malign
previous
describ
mortal
increas
patient
pneumonia
initi
appropri
antimicrobi
therapi
viral
infect
delay
lymphocyt
reconstitut
develop
endorgan
diseas
associ
wors
outcom
prior
studi
sever
cap
requir
icu
admiss
immunosuppress
includ
patient
receiv
radiat
chronic
steroid
receiv
cytotox
therapi
associ
increas
risk
mortal
multivari
analysi
mortal
higher
cancer
develop
vap
multivari
analysi
studi
cancer
patient
develop
acut
respiratori
failur
almost
die
surviv
associ
cardiogen
pulmonari
edema
poor
anyon
mechan
ventil
requir
goal
care
revisit
anyon
respond
first
h
icu
care
particularli
set
progress
malign
need
mechan
ventil
sinc
mortal
exceedingli
high
respiratori
tract
infect
occur
commonli
cancer
patient
contribut
substanti
morbid
mortal
noninfecti
infiltr
occur
commonli
patient
consid
differenti
diagnosi
recent
molecular
method
improv
capac
diagnos
pathogen
respons
pneumonia
frequent
empir
therapi
still
necessari
take
account
patient
underli
risk
factor
multidrugresist
pathogen
virus
fungi
sinc
mani
pathogen
caus
diseas
popul
respond
empir
therapi
aggress
diagnost
test
tissu
sampl
necessari
help
focu
treatment
modal
